cancerspЮжно-Российский онкологический журнал/ South Russian Journal of CancerSouth Russian Journal of Cancer2686-9039АНО "Перспективы онкологии"10.37748/2687-0533-2020-1-2-6cancersp-59Research ArticleКлинические наблюденияCLINICAL CASE REPORTSГОРМОНОПОЛОЖИТЕЛЬНЫЙ HER2-НЕГАТИВНЫЙ МЕТАСТАТИЧЕСКИЙ РАК МОЛОЧНОЙ ЖЕЛЕЗЫ: ПРИНЯТИЕ РЕШЕНИЙ В РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕHORMONE-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER: DECISION MAKING IN REAL CLINICAL PRACTICEhttps://orcid.org/0000-0003-4236-6476ВладимироваЛ. Ю.VladimirovaL. Yu.

д.м.н., профессор, руководитель отдела лекарственного лечения опухолей, руководитель отделенияпротивоопухолевой лекарственной терапии № 1

SPIN: 4857–6202, Author ID: 289090, Researcher ID: U-8132–2019, Scopus Author ID: 7004401163 344037, Российская Федерация, г. Ростов-на-Дону, ул. 14-я линия, д. 63

Dr. Sci. (Med.), Professor, head of the tumor drug treatment department, head of the antitumor drug therapy department No. 1

SPIN: 4857–6202, AuthorID: 289090, ResearcherID: U-8132–2019, Scopus Author ID: 7004401163

63 14 line str., Rostov-on-Don 344037, Russian Federation

https://orcid.org/0000-0003-0965-0264СторожаковаА. Э.StorozhakovaA. E.

Cand. Sci. (Med.), head of the antitumor drug therapy department No. 2

SPIN: 2804–7474, AuthorID: 734057, ResearcherID: U-6202–2019, Scopus Author ID: 57045921800

63 14 line str., Rostov-on-Don 344037, Russian Federation

maymur@list.ruhttps://orcid.org/0000-0002-9661-9312СнежкоТ. А.SnezhkoT. A.

к.м.н., врач отделения противоопухолевой лекарственной терапии № 2

SPIN: 4479–1414, Author ID: 706064, Scopus Author ID: 57189055248

344037, Российская Федерация, г. Ростов-на-Дону, ул. 14-я линия, д. 63 

Cand. Sci. (Med.), doctor of the antitumor drug therapy department No. 2

SPIN: 4479–1414, AuthorID: 706064, Scopus Author ID: 57189055248

63 14 line str., Rostov-on-Don 344037, Russian Federation

https://orcid.org/0000-0001-9517-246XСтраховаЛ. К.StrakhovaL. K.

младший научный сотрудник отдела лекарственного лечения опухолей

SPIN: 2688–1073, AuthorID: 1055704 344037, Российская Федерация, г. Ростов-на-Дону, ул. 14-я линия, д. 63 

junior researcher of the tumor drug treatment department

SPIN: 2688–1073, AuthorID: 1055704

63 14 line str., Rostov-on-Don 344037, Russian Federation

https://orcid.org/0000-0001-7793-9794АбрамоваН. А.AbramovaN. A.

к.м.н., врач-онколог отделения противоопухолевой лекарственной терапии № 1, старший научныйсотрудник отдела лекарственного лечения опухолей

SPIN: 1784–8819, Author ID: 734048, Researcher ID: U-6181–2019, Scopus Author ID: 56737398800 344037, Российская Федерация, г. Ростов-на-Дону, ул. 14-я линия, д. 63

Cand. Sci. (Med.), oncologist of the antitumor drug therapy department No. 1, senior researcher of the tumor drug treatmentdepartment

SPIN: 1784–8819, AuthorID: 734048, ResearcherID: U-6181–2019, Scopus Author ID: 56737398800

63 14 line str., Rostov-on-Don 344037, Russian Federation

https://orcid.org/0000-0001-8628-4240КабановС. Н.KabanovS. N.

к.м.н., врач отделения противоопухолевой лекарственной терапии № 2

SPIN: 6369–0824, Author ID: 794858, Researcher ID: V-3023–2019, Scopus Author ID: 57045732600 344037, Российская Федерация, г. Ростов-на-Дону, ул. 14-я линия, д. 63

Cand. Sci. (Med.), doctor of the antitumor drug therapy department № 2

SPIN: 6369–0824, AuthorID: 794858, ResearcherID: V-3023–2019, Scopus Author ID: 57045732600

63 14 line str., Rostov-on-Don 344037, Russian Federation

https://orcid.org/0000-0003-0158-3757КалабановаЕ. А.KalabanovaE. A.

к.м.н., старший научный сотрудник отдела лекарственного лечения опухолей

SPIN: 9090–3007, Author ID: 734992, Researcher ID: V-2943–2019, Scopus Author ID: 57046062200 344037, Российская Федерация, г. Ростов-на-Дону, ул. 14-я линия, д. 63

Cand. Sci. (Med.), Senior researcher of the tumor drug treatment department

SPIN: 9090–3007, AuthorID: 734992, ResearcherID: V-2943–2019, Scopus Author ID: 57046062200

63 14 line str., Rostov-on-Don 344037, Russian Federation

https://orcid.org/0000-0003-0843-6012СаманеваН. Ю.SamanevaN. Yu.

врач отделения противоопухолевой лекарственной терапии № 2

SPIN: 1181–0659, Author ID: 734488, Researcher ID: AAH-7905–2019, Scopus Author ID: 57192874030 344037, Российская Федерация, г. Ростов-на-Дону, ул. 14-я линия, д. 63

doctor of the antitumor drug therapy department No. 2

SPIN: 1181–0659, AuthorID: 734488, ResearcherID: AAH-7905–2019, Scopus Author ID: 57192874030

63 14 line str., Rostov-on-Don 344037, Russian Federation

https://orcid.org/0000-0001-5371-0709СветицкаяЯ. В.SvetitskayaYa. V.

к.м.н., научный сотрудник отдела лекарственного лечения опухолей

SPIN: 6821–0327, Author ID: 571593, Researcher ID: AAH-7906–2019 344037, Российская Федерация, г. Ростов-на-Дону, ул. 14-я линия, д. 63

Cand. Sci. (Med.), scientific researcher of the tumor drug treatment department 

SPIN: 6821–0327, AuthorID: 571593, ResearcherID: AAH-7906–2019

63 14 line str., Rostov-on-Don 344037, Russian Federation

https://orcid.org/0000-0002-7990-8710ТишинаА. В.TishinaA. V.

врач отделения противоопухолевой лекарственной терапии № 2

SPIN: 7686–3707, Researcher ID: H-2460–2018 344037, Российская Федерация, г. Ростов-на-Дону, ул. 14-я линия, д. 63

doctor of the antitumor drug therapy department № 2

SPIN: 7686–3707, ResearcherID: H-2460–2018

63 14 line str., Rostov-on-Don 344037, Russian Federation

ФГБУ «НМИЦ онкологии» Минздрава РоссииРоссияNational Medical Research Centre for Oncology of the Ministry of Health of RussiaRussian FederationФГБУ «НМИЦ онкологии» Минздрава России,РоссияNational Medical Research Centre for Oncology of the Ministry of Health of RussiaRussian Federation202002062020124651Copyright © Владимирова Л.Ю., Сторожакова А.Э., Снежко Т.А., Страхова Л.К., Абрамова Н.А., Кабанов С.Н., Калабанова Е.А., Саманева Н.Ю., Светицкая Я.В., Тишина А.В., 20202020Владимирова Л.Ю., Сторожакова А.Э., Снежко Т.А., Страхова Л.К., Абрамова Н.А., Кабанов С.Н., Калабанова Е.А., Саманева Н.Ю., Светицкая Я.В., Тишина А.В.Vladimirova L.Y., Storozhakova A.E., Snezhko T.A., Strakhova L.K., Abramova N.A., Kabanov S.N., Kalabanova E.A., Samaneva N.Y., Svetitskaya Y.V., Tishina A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.cancersp.com/jour/article/view/59метастатический рак молочной железыгормонотерапияциклинзависимые киназырибоциклибпалбоциклибабемациклибmetastatic breast cancerhormone therapycyclin‑dependent kinasesribocyclibpalbocyclibabemacyclibReferencesAnderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002 Nov; 76(1): 27–36. https://doi.org/10.1023/a:1020299707510Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002 Nov; 76(1): 27–36. https://doi.org/10.1023/a:1020299707510Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, et al. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2015 Nov 1; 21(21): 4760–4766. https://doi.org/10.1158/1078–0432.CCR-15–1185Beaver JA, Amiri‑Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, et al. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor‑Positive, HER2‑Negative Metastatic Breast Cancer. Clin Cancer Res. 2015 Nov 1; 21(21): 4760–4766. https://doi.org/10.1158/1078–0432.CCR‑15–1185Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016 Dec 17; 388(10063): 2997–3005. https://doi.org/10.1016/S0140–6736 (16)32389–3Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor‑positive advanced breast cancer (FALCON): an international, randomised, double‑blind, phase 3 trial. Lancet. 2016 Dec 17; 388(10063): 2997–3005. https://doi.org/10.1016/S0140–6736(16)32389–3Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol. 2014 Oct; 25(10): 1871–1888. https://doi.org/10.1093/annonc/mdu385Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, et al. ESO‑ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol. 2014 Oct; 25(10): 1871–1888. https://doi.org/10.1093/annonc/mdu385Fan W, Chang J, Fu P. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. Future Med Chem. 2015 Aug; 7(12): 1511–1519. https://doi.org/10.4155/fmc.15.93Fan W, Chang J, Fu P. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. Future Med Chem. 2015 Aug; 7(12): 1511–1519. https://doi.org/10.4155/fmc.15.93Boye E, Grallert B. The 2001 Nobel Prize in Physiology or Medicine. Tidsskr Nor Laegeforen. 2001 Dec 10; 121(30): 3500.Boye E, Grallert B. The 2001 Nobel Prize in Physiology or Medicine. Tidsskr Nor Laegeforen. 2001 Dec 10; 121(30): 3500.Rugo HS, Finn RS, Dieras V, Ettl J, Lipatov O, Joy A, et al. Abstract P5–21–03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups. Cancer Res. 2018 Feb 15; 78(4 Supplement): P5-P5–21–03. https://doi.org/10.1158/1538–7445.SABCS17-P5–21–03Rugo HS, Finn RS, Dieras V, Ettl J, Lipatov O, Joy A, et al. Abstract P5–21–03: Palbociclib (PAL) + letrozole (LET) as first‑line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Efficacy and safety updates with longer follow‑up across patient subgroups. Cancer Res. 2018 Feb 15; 78(4 Supplement): P5‑P5–21–03. https://doi.org/10.1158/1538–7445.SABCS17‑P5–21–03Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018 Jul 1; 29(7): 1541–1547. https://doi.org/10.1093/annonc/mdy155Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch‑Shimon S, et al. Updated results from MONALEESA‑2, a phase III trial of first‑line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor‑positive, HER2‑negative advanced breast cancer. Ann Oncol. 2018 Jul 1; 29(7): 1541–1547. https://doi.org/10.1093/annonc/mdy155Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017 Nov 10; 35(32): 3638–3646. https://doi.org/10.1200/JCO.2017.75.6155Goetz MP, Toi M, Campone M, Sohn J, Paluch‑Shimon S, Huober J, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017 Nov 10; 35(32): 3638–3646. https://doi.org/10.1200/JCO.2017.75.6155Артамонова Е. В. Практические аспекты клинического применения нового класса препаратов — ингибиторов циклинзависимых киназ: эффективность и переносимость лечения. Опухоли женской репродуктивной системы 2018; 14(1): 52–60.Artamonova EV. Practical aspects of administering cyclin‑dependent kinases inhibitors: efficacy and tolerability. Journal of Tumors of the Female Reproductive System 2018; 14(1): 52–60. (In Russian).

The authors declare that there are no conflicts of interest present.